Ken Cunningham, who recently joined the board of UK pharmaceutical and particle engineering company Prosonix, will lead the company’s new scientific advisory board. Joining Cunningham on Prosonix’s SAB are: Peter Barnes, Professor of Thoracic Medicine and Head of Airway Disease, National Heart and Lung Institute, and Honorary Consultant Physician, Royal Brompton Hospital, London; Marianne Mann, consultant and former FDA Deputy Director of the Division of Pulmonary and Allergy Drug Products; and John Pritchard, Chief Technology Officer at Philips’ Respironics drug delivery unit
Prosonix CEO David Hipkiss explained the company’s decision to form the new advisory board: “The formation of our first formal Scientific Advisory Board is a significant step for Prosonix, signalling our strong intent to build on our past successes and advance the development of our pipeline of respiratory drug candidates into the clinic and towards regulatory approval. In particular, the next 12 months will see the Company prepare to file PSX1001 in Europe for asthma based on strong in vitro bioequivalence data, being potentially the first company to do so.”
Hipkiss said that Prosonix also anticipates that it will be soon begin development of its first PSX2000 combination therapy and will initiate a Phase 2 proof of concept clinical study with PSX1002 in COPD. “We are therefore delighted to announce the new members of our SAB,” he said, “all of whom are distinguished experts in their relevant fields and will provide invaluable advice and guidance to the Company during this exciting period.”
Read the Prosonix press release.
